Q32 Bio Inc.
QTTBHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframeQ32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven. With a market capitalization of $356.9M, it sits in small-cap territory. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata.
Market Cap
$356.9M
Beta
-0.38
P/E (TTM)
3.82
P/E (Fwd)
-11.75
EPS (TTM)
$3.14
EPS (Fwd)
$-1.02
ROE
72.1%
ROA
14.7%
Cash
$106.3M
Total Debt
$5.3M
Free CF
$19.4M
52W Change
573.6%
Annual Financials
Cash vs Debt
Where QTTB stands vs its 150-day and 200-day moving averages
As of the August 4, 2026 close, QTTB finished 95.36% above its 150-day moving average ($7.76) and 132.52% above its 200-day moving average ($6.52). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is QTTB overbought or oversold?
At the August 4, 2026 close, QTTB's RSI(14) was 29.0, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Q32 Bio Inc. holds $106.3M in cash against $5.3M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company generates $19.4M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 72.1% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 14.7% further supports the picture of efficient asset utilization. Revenue has grown from $6.7M (2022) to $53.7M (2025), reflecting a 708% increase over the period.
QTTB's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. No single metric tells the full story. Reviewing QTTB's risk profile alongside its fundamentals and technical indicators provides a more complete picture.